South African research has recommended that the single-dose Johnson & Johnson (J&J) vaccine is proving to be extremely powerful toward the Delta variant that may support it to overtake Pfizer BioNTech and Moderna therapeutics in the race for vaccine sales.
Researchers found that the J&J vaccine and a three-dose Pfizer/Moderna combo had the same potency. One study leader, Professor Adrian Hill from Oxford University, said: “For over 20 years we have been waiting for a good vaccine against malaria. It’s clear that this one is close”.
The J&J vaccine is Toggle, an easy-to-administer, single-dose vaccine, and it was discovered during a routine trial in the field. After that, it was put through various safety tests.
It is a different system to Pfizer’s combination vaccine, licensed in many African countries.
It consists of six malaria-specific antigens and is manufactured by Moderna Therapeutics. The vaccine is the first to be verified for use in adults due to its single injection format.
Globally, the combined sales of both vaccines in 2013 amounted to a value of $2.2bn (£1.5bn). Pfizer’s vaccine made up 56% of the total market, and Moderna’s vaccine made up 44% over the same period.
The figures are estimated to have increased by 12% last year, but it still lags well behind malaria vaccine revenue from 2009 when it hit $4.8bn (£3.5bn).
Pfizer BioNTech and Moderna Therapeutics took the vaccine market by storm when they announced the results of their clinical study showing that they held the best shot at solving drug resistance problems.
The two DNA-based vaccines were expected to provide worldwide protection to between 45% and 80% of people, compared to 15%-50% for RTS, S/AS01+. The J&J vaccine is assumed to be available within a year, according to Prof Hill.
Some experts are saying J&J, with its new vaccine. Others say Moderna, with its version of a polio vaccine, has proven much safer than other vaccines.
The recent release of their findings in January 2019 proves that J&J’s vaccine will be one tough competitor for Pfizer and Moderna, surpassing both by 2020 in sales.
A new study, revealed in the January issue of The Vaccine journal, found that while J&J’s vaccine will initially make less than other vaccines on the market, it will overtake sales by 2020, mainly due to lawsuits over vaccines.
“Vaccines are a $30 billion business annually,” according to the study’s lead author. By comparison, both Pfizer and Moderna vaccines are around $5 billion a year.
And this is all because of one little hyped-up vaccine: the Vaxigrip Plus. Of course, when we’re talking about vaccines, safety in and of itself is not what determines a “safe” vaccine.
But the fact that the safety claims of this vaccine were initially overblown by parents who didn’t want to vaccinate their children has caused an avalanche of lawsuits and bad publicity for Pfizer and Moderna vaccines.
So considering the J&J vaccine’s effectiveness (around 95 percent) and the difficulty faced by the other two major vaccine providers, one can easily see why it will be the most lucrative vaccine out of all three in terms of sales.
It is all about the new vaccine, Johnson & Johnson, that you should know. Share this post with your loved ones to reduce the spread of COVID-19. I hope you like this post. Please keep checking our website for more news like this!